BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bębnowska D, Grywalska E, Niedźwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Góźdź S, Roliński J, Polkowski W. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. J Clin Med 2020;9:E1894. [PMID: 32560392 DOI: 10.3390/jcm9061894] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Islas JF, Quiroz-reyes AG, Delgado-gonzalez P, Franco-villarreal H, Delgado-gallegos JL, Garza-treviño EN, Gonzalez-villarreal CA. Cancer Stem Cells in Tumor Microenvironment of Adenocarcinoma of the Stomach, Colon, and Rectum. Cancers 2022;14:3948. [DOI: 10.3390/cancers14163948] [Reference Citation Analysis]
2 Huang B, Miao L, Liu J, Zhang J, Li Y. A promising antitumor method: Targeting CSC with immune cells modified with CAR. Front Immunol 2022;13:937327. [DOI: 10.3389/fimmu.2022.937327] [Reference Citation Analysis]
3 Sun J, Li X, Chen P, Gao Y. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. J Inflamm Res 2022;15:4061-85. [PMID: 35873388 DOI: 10.2147/JIR.S368138] [Reference Citation Analysis]
4 Jin X, Liu Z, Yang D, Yin K, Chang X. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Front Immunol 2022;13:948647. [DOI: 10.3389/fimmu.2022.948647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives. Int J Mol Sci 2022;23:6664. [PMID: 35743107 DOI: 10.3390/ijms23126664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Oh S, Yang H, Oh HR, Seo M, Lee C, Kim Y, Choi JY, Kim NY, Cheon GJ, Kang KW, Shin YK, Youn H. Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.04.003] [Reference Citation Analysis]
7 Bao T, Wang Z, Xu J. Immune-Related lncRNAs Pairs to Construct a Novel Signature for Predicting Prognosis in Gastric Cancer. Front Surg 2022;9:807778. [DOI: 10.3389/fsurg.2022.807778] [Reference Citation Analysis]
8 Faghfuri E, Shadbad MA, Faghfouri AH, Soozangar N. Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. Immunotherapy 2022. [PMID: 35232264 DOI: 10.2217/imt-2021-0285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kole C, Charalampakis N, Tsakatikas S, Kouris NI, Papaxoinis G, Karamouzis MV, Koumarianou A, Schizas D. Immunotherapy for gastric cancer: a 2021 update. Immunotherapy 2021. [PMID: 34784774 DOI: 10.2217/imt-2021-0103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Qian S, Villarejo-Campos P, García-Olmo D. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications. J Clin Med 2021;10:5050. [PMID: 34768570 DOI: 10.3390/jcm10215050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev 2021;100:102288. [PMID: 34525422 DOI: 10.1016/j.ctrv.2021.102288] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
12 Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Reference Citation Analysis]
13 Kyuno D, Takasawa A, Takasawa K, Ono Y, Aoyama T, Magara K, Nakamori Y, Takemasa I, Osanai M. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers 2021;:1967080. [PMID: 34486479 DOI: 10.1080/21688370.2021.1967080] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188615. [PMID: 34403771 DOI: 10.1016/j.bbcan.2021.188615] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
15 Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
16 Yu J, Liu H, Zeng X, Zhao Y, Jiang D, Lu H, Qian J. Prognostic and clinicopathological significance of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer: A meta-analysis. PLoS One 2021;16:e0250295. [PMID: 33901218 DOI: 10.1371/journal.pone.0250295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Fernandez-Rozadilla C, Simões AR, Lleonart ME, Carnero A, Carracedo Á. Tumor Profiling at the Service of Cancer Therapy. Front Oncol 2020;10:595613. [PMID: 33505911 DOI: 10.3389/fonc.2020.595613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Chen Y, Zhou Q, Wang H, Zhuo W, Ding Y, Lu J, Wu G, Xu N, Teng L. Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers. Cancers (Basel) 2020;12:E2236. [PMID: 32785164 DOI: 10.3390/cancers12082236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]